Using 68Ga-grazytracer PET to monitor immunotherapy responses in liver cancer
Official title: A Prospective Study on Investigating the Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
Run by Ruijin Hospital · NCT06597539 · Data updated 2026-11-12
This study is testing if a special type of imaging can help doctors see how well immunotherapy is working for people with advanced liver cancer after a few treatment cycles.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Ruijin Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | November 9, 2024 |
| Main results expected | June 30, 2026 |
| Study ends | July 31, 2027 |
| Registry record updated | December 11, 2024 |
| Trial ID | NCT06597539 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-75 with advanced hepatobiliary malignancies who are eligible for immunotherapy.
✕Probably not a fit
Patients with serious comorbidities or those who are non-compliant with study procedures may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of 68Ga-grazytracer PET/CT imaging in predicting how well patients with advanced hepatobiliary malignancies respond to immunotherapy. Participants will undergo imaging after three cycles of treatment, and the results will be compared to standard clinical assessments to determine the accuracy of the imaging technique. The study aims to enhance the understanding of immunotherapy efficacy in this patient population.
Why it matters
Potential benefit: If successful, this study could provide a reliable imaging method to assess treatment responses, potentially leading to better patient management and outcomes.
How similar studies have gone: While the use of PET imaging in monitoring treatment responses is established, the specific application of 68Ga-grazytracer PET in this context is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pathological and clinical diagnosis of advanced hepatobiliary malignancy requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines 2. Signed and dated informed consent form 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process 4. aged 18-75 years old 5. The patient is in good general condition with an expected survival of \> 6 months Exclusion Criteria: 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. Intestinal perforation, complete intestinal obstruction 3. Uncontrolled diabetes patients or fasting blood glucose levels ≥11 mmol/L on the day of the trial 4. Pregnant women and women who may be pregnant, women who are breastfeeding. 5. Non-compliant person
Where it's running
-
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Jiajia Hu
- Email: jiajiahu@shsmu.edu.cn
- Phone: 0086-13524945287
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fluoxetine added to immunotherapy for advanced liver and gallbladder cancer with depression or anxiety
This trial will test whether adding the antidepressant fluoxetine to standard PD-1/PD-L1 immunotherapy helps people with advanced liver or gallbladder cancers who also have depression or anxiety.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.